Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth.

Genome research - 1 Mar 2018

Kim Wonjoo, Lee Sangeun, Kim Han Sang, Song Minjung, Cha Yong Hoon, Kim Young-Hoon, Shin Jeonghong, Lee Eun-Seo, Joo Yeonsoo, Song Jae J, Choi Eun Ju, Choi Jae W, Lee Jinu, Kang Moonkyung, Yook Jong In, Lee Min Goo, Kim Yeon-Soo, Paik Soonmyung, Kim Hyongbum Henry

Abstract excerpt

KRAS is the most frequently mutated oncogene in human tumors, and its activating mutations represent important therapeutic targets. The combination of Cas9 and guide RNA from the CRISPR-Cas system recognizes a specific DNA sequence and makes a double-strand break, which enables editing of the relevant genes. Here, we harnessed CRISPR to specifically target mutant KRAS alleles in cancer cells. We screened guide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Cas Systems

Share to Gene Editing

Share to Lentivirus

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to RNA, Guide, CRISPR-Cas Systems

Source

Open in PubMed Open full text

Identifiers

PMID: 29326299
DOI: 10.1101/gr.223891.117
PMCID: PMC5848616

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth.PMID 29326299Read ↗

Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells.Semantic proximity Read ↗

CRISPR and KRAS: a match yet to be made.Semantic proximity Read ↗

Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression.Semantic proximity Read ↗

Selective targeting of an oncogenic <i>KRAS</i> mutant allele by CRISPR/Cas9 induces efficient tumor regressionSemantic proximity Read ↗

Engineering CRISPR/Cas9 therapeutics for cancer precision medicineSemantic proximity Read ↗

Precision Oncology in the CRISPR Era: Applications and Future Horizons in Cancer TherapySemantic proximity Read ↗

Precision Oncology in the CRISPR Era: Applications and Future Horizons in Cancer TherapySemantic proximity Read ↗

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing.Semantic proximity Read ↗

A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.Semantic proximity Read ↗

Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.Semantic proximity Read ↗

A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing.Semantic proximity Read ↗

CRISPR/Cas9 and cancer targets: future possibilities and present challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.